Torrent Pharma

Sector: Pharmaceuticals  |  HQ: Ahmedabad, Gujarat, India  |  Founded: 1959  |  Employees: 16,000+

Listed as: NSE / BSE listed (TORNTPHARM)  |  NSE / BSE  |  Ticker: TORNTPHARM.NS

Company overview

Torrent Pharmaceuticals is the flagship pharmaceutical company of the Torrent Group, founded in 1959 by U N Mehta in Ahmedabad. The company is one of India's largest pharmaceutical companies by market capitalisation and revenue, with a portfolio anchored in branded formulations for the Indian market and supplemented by exports to Brazil, the United States, Germany, the United Kingdom, the Philippines and other geographies. Torrent's flagship therapy areas include cardiovascular, central nervous system, gastrointestinal, diabetology, pain management, women's health and dermatology, where it has built strong prescription brands such as Shelcal, Chymoral, Unienzyme, Nikoran and Dilzem. The Mehta family controls Torrent Pharma through Torrent Investments and other group entities. The company is listed on the BSE and NSE, is a constituent of the Nifty Pharma index, and is widely tracked by Indian and global pharma investors. Manufacturing is anchored at multiple plants in India, with secondary manufacturing in Germany. Group sister company Torrent Power is one of India's significant private electricity utilities.

Financial performance and recent trajectory

Disclosed revenue (FY25): ₹11,500 crore (FY 2024-25 estimate).

12-month price trajectory

Monthly closes over the last 12 months. Source: Yahoo Finance.

Competitive position

Torrent Pharma is among the top eight pharmaceutical companies in the Indian branded formulations market alongside Sun Pharmaceutical, Cipla, Mankind Pharma, Lupin, Alkem, Dr Reddy's and Aurobindo. It ranks among the top three companies in cardiovascular and central nervous system therapies in India, and is a major player in chronic and lifestyle therapies more broadly. Internationally, Torrent has a meaningful Brazil business that ranks among the top fifteen in the local market and a Germany business that emphasises specialty generics. In the United States generic market, Torrent has a smaller and more focused presence centred on a curated portfolio.

Key risks

NPPA pricing controls on essential medicines US FDA inspection and compliance risk Currency volatility on international businesses

Outlook

Torrent Pharmaceuticals traces its origins to 1959 when U N Mehta founded Trinity Laboratories in Ahmedabad to manufacture and distribute pharmaceutical formulations. The business was renamed Torrent Pharma in subsequent decades and built a strong domestic branded formulations franchise through the 1970s and 1980s. Sudhir Mehta and Samir Mehta, sons of the founder, took the business through its modernisation and listing in the 1990s. The modern phase of Torrent's growth has been shaped by domestic acquisitions and international expansion. The acquisition of Heumann Pharma in Germany in 2005 gave Torrent a generic foothold in Europe's largest pharma market. In India the acquisition of Elder Pharmaceuticals' domestic branded business in 2014 for around ₹2,000 crore added Shelcal, Chymoral and other strong brands and propelled Torrent into the top tier of the Indian domestic market. Subsequent bolt on acquisitions of branded portfolios from Bio Med, Curatio Healthcare and others have continued to scale up domestic depth, particularly in women's health and dermatology. The Curatio Healthcare acquisition in 2022 for around ₹2,000 crore brought the Tedibar baby care, B4 Nappi and other paediatric dermatology brands and gave Torrent a leadership position in dermatology. The 2023 acquisition of a stake in JB Chemicals was contemplated but did not materialise, while the contemplated acquisition of Cipla was a topic of trade press speculation in 2023 and 2024. The business is organised into India branded formulations as the largest segment by revenue and by far the most profitable, contract development and manufacturing services that include the JS Mehta facility, and international branded and generics businesses in Brazil, Germany, the United States, the United Kingdom, the Philippines and select rest of world markets. Product portfolio in India spans cardiovascular brands like Dilzem and Nikoran, central nervous system brands including a portfolio of antidepressants and antipsychotics, gastrointestinal brands including Unienzyme and Chymoral, pain management, calcium supplementation under Shelcal, vitamins, dermatology under the Curatio portfolio, women's health and a growing biosimilar pipeline. The company has more than ten brands with annual revenue of more than ₹100 crore each in India, a metric of franchise strength. Manufacturing footprint includes US FDA approved plants at Indrad and Dahej in Gujarat for formulations, Bileshwarpura for active pharmaceutical ingredients, and Pithampur in Madhya Pradesh, alongside Heumann's plant in Germany. The Indian plants serve domestic and export markets across regulated and semi regulated geographies. The company has consistently invested in regulatory upgrades, automation and quality systems. Distribution in India is through more than 4,500 medical representatives covering approximately 6,00,000 doctors and a stockist network spanning the country. Brazil distribution is through the local subsidiary that operates as Torrent do Brasil and is one of the larger Indian pharma franchises in Latin America. Financial trajectory has been strong. Revenue has grown at a high single digit compounded rate over the past decade, FY 2024-25 consolidated revenue is estimated at around ₹11,500 crore, operating margins are in the high twenties to low thirties percent reflecting the high share of branded formulations in India and Brazil, and return on capital has been a focus of management messaging. The company has progressively reduced leverage and now operates with a moderate net debt to equity ratio. Recent capex has been moderate. Strategic capital has been deployed in acquisitions rather than greenfield capacity, with selective investment in biosimilars and complex generics. Mergers and acquisitions activity has been heavy, with Curatio integration completed, smaller bolt ons in branded formulations, and recurring market speculation about larger deals. Strategy 2025 to 2030 focuses on continued leadership in India branded formulations through high single digit volume growth, premiumisation, biosimilars and chronic therapies, scaling up Brazil and Germany branded generics, selective US generics growth in differentiated portfolio, and inorganic growth where value accretive. Sustainability of operating margins above 30 percent is a stated management ambition. The regulatory environment is shaped by the Drugs and Cosmetics Act 1940, the Drugs Price Control Order under the Essential Commodities Act, the New Drugs and Clinical Trials Rules 2019, US FDA and EMA inspections for export plants, Anvisa for Brazil, the Companies Act 2013 and SEBI LODR for listed company obligations, and increasing biosimilar specific regulation. The company has historically maintained a strong inspection record with intermittent observations addressed proactively. Risks include pricing pressure from the National Pharmaceutical Pricing Authority on essential medicines in India, US FDA inspection outcomes, currency volatility on the Brazil and Europe businesses, integration risk on acquired portfolios, intensifying competition in the Indian branded market from Mankind and Sun, and the broader risk of consolidation altering relative positioning. Management is led by Samir Mehta as executive chairman and Aman Mehta as whole time director, with a deep professional bench across India, Brazil and Germany operations. Governance follows SEBI LODR with full independent director representation, audit, nomination and remuneration committees, risk management and corporate social responsibility committees. ESG profile includes water, energy and emissions targets, supplier code of conduct, an active corporate social responsibility programme through UNM Foundation focused on rural health, education and community wellbeing, and routine BRSR disclosure. Patient access programmes for cardiac and neurology medicines have been part of the franchise narrative.

KAMRIT point of view

Building or competing with Torrent?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharmaceuticals sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Torrent and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use Torrent Pharma in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.